ZDA
TLSI icon

Zweig-DiMenna Associates’s TriSalus Life Sciences TLSI Stock Holding History

Zweig-DiMenna Associates’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-90,000
Closed -$889K – 146
2021
Q4 		$889K Hold
90,000
– – 0.07% 113
2021
Q3 		$894K Buy
+90,000
New +$881K 0.06% 145

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Zweig-DiMenna Associates's TLSI Position: Q1 2022 in Review

Zweig-DiMenna Associates sold out of TriSalus Life Sciences (TLSI) in Q1 2022, closing a stake of 90,000 shares — an estimated $889K sold.

Zweig-DiMenna Associates first reported a position in TLSI in Q3 2021 and held it in 2 quarters. The position peaked at $894K in Q3 2021. 68 funds tracked by Wall St. Rank hold TLSI as of Q1 2022.

  • Zweig-DiMenna Associates reported no remaining TriSalus Life Sciences position as of Q1 2022 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 90,000 TriSalus Life Sciences shares in Q1 2022, an estimated $889K.
  • Zweig-DiMenna Associates first reported a position in TriSalus Life Sciences in Q3 2021 and held it in 2 quarters.
  • Zweig-DiMenna Associates's TriSalus Life Sciences position peaked at $894K in Q3 2021.
  • 68 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2022.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2022, filed 25 Apr 2022.